Literature DB >> 815434

Serum factors activating the alternative complement pathway in autoimmune disease: description of two different factors from patients with systemic lupus erythematosus.

C M Arroyave, M R Wilson, E M Tan.   

Abstract

Serum factors which activated the alternative pathway of complement were detected in 10 of 26 patients with systemic lupus erythematosus (SLE), three of 18 patients with mixed connective tissue disease, one patient with scleroderma, and one with Sjögren's syndrome. This activation was detected by conversion of factor B and C3 into split products and by lysis of glutathione-sensitized human erythrocytes under conditions where classical pathway activation was blocked. The serum factors capable of activating the alternative pathway could be seperated into 7S and 19S-type molecules by sucrose density gradient ultracentrifugation. In two patients with SLE, serum factors were isolated by ion-exchange chromatography, preparative electrophoresis, and molecular sieve chromatography. The serum 7S factor was immunochemically identical to the C3 nephritic factor (C3NeF) of hypocomplementemic chronic glomerulonephritis. Antisera to other complement components failed to react with this purified material. The 7S factor was able to activate the alternative pathway in C2 deficient serum, and in normal human serum under conditions where classical pathway was blocked, but was unable to do so in sera depleted of factor B, factor D, and C3. The activity could be removed by antiserum to C3NeF. In contrast, the serum 19S activator of the alternative pathway was not reactive with antiserum to C3NeF. It had a fast gamma mobility on electrophoresis and the activity could be removed by absorption with anti-IgG and anti-IgM. It was suggested that the 19S factors could consist, in part, of immune complexes.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 815434

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  13 in total

1.  Heterogeneity of nephritic factor and its identification as an immunoglobulin.

Authors:  A E Davis; J B Ziegler; E W Gelfand; F S Rosen; C A Alper
Journal:  Proc Natl Acad Sci U S A       Date:  1977-09       Impact factor: 11.205

2.  Immune reactants in cryoproteins. Relationship to complement activation.

Authors:  M R Wilson; C M Arroyave; L Miles; E M Tan
Journal:  Ann Rheum Dis       Date:  1977-12       Impact factor: 19.103

3.  Human blood cells ultrastructural changes and mediator release after exposure to roentgenographic contrast media.

Authors:  M J Fritzler; J Ring; C M Arroyave; E M Tan
Journal:  Can Med Assoc J       Date:  1978-10-21       Impact factor: 8.262

4.  Effects of coagulation temperature on measurements of complement function in serum samples from patients with systemic lupus erythematosus.

Authors:  G Baatrup; G Sturfelt; A Junker; S E Svehag
Journal:  Ann Rheum Dis       Date:  1992-07       Impact factor: 19.103

5.  Targeting the Complement Alternative Pathway Permits Graft Versus Leukemia Activity while Preventing Graft Versus Host Disease.

Authors:  Hung Nguyen; Ali Alawieh; David Bastian; Sandeepkumar Kuril; Min Dai; Anusara Daenthanasanmak; Mengmeng Zhang; Supinya Iamsawat; Steven D Schutt; Yongxia Wu; M Mahdi Sleiman; Akshay Shetty; Carl Atkinson; Shaoli Sun; Juan Carlos Varela; Stephen Tomlinson; Xue-Zhong Yu
Journal:  Clin Cancer Res       Date:  2020-01-09       Impact factor: 12.531

6.  Activation of the alternative complement pathway in systemic lupus erythematosus.

Authors:  M R Wilson; C M Arroyave; R M Nakamura; J H Vaughan; E M Tan
Journal:  Clin Exp Immunol       Date:  1976-10       Impact factor: 4.330

7.  Complement activating cryoglobulins in the nephritis of systemic lupus erythematosus.

Authors:  D Adu; D G Williams
Journal:  Clin Exp Immunol       Date:  1984-03       Impact factor: 4.330

8.  Development and application of an enzyme-linked immunosorbent assay for the quantitation of alternative complement pathway activation in human serum.

Authors:  J T Mayes; R D Schreiber; N R Cooper
Journal:  J Clin Invest       Date:  1984-01       Impact factor: 14.808

9.  Reduced complement-mediated immune complex solubilizing capacity and the presence of incompletely solubilized immune complexes in SLE sera.

Authors:  G Baatrup; I Petersen; J C Jensenius; S E Svehag
Journal:  Clin Exp Immunol       Date:  1983-11       Impact factor: 4.330

10.  In vitro histamine and serotonin release by radiographic contrast media (RCM). Complement-dependent and -independent release reaction and changes in ultrastructure of human blood cells.

Authors:  J Ring; C M Arroyave; M J Frizler; E M Tan
Journal:  Clin Exp Immunol       Date:  1978-04       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.